Armistice Capital »

Prothena shares owned by Armistice Capital

Quarter-by-quarter ownership of Prothena (PRTA) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Prothena

Tip: Access up to 7 years of quarterly data

All positions including Prothena held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Prothena by Armistice Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $32M 1.6M 20.64
2024-03-31 $27M 1.1M 24.77

More positions owned by Armistice Capital

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Ptc Therapeutics I (PTCT)
Cytokinetics Com New (CYTK)
Supernus Pharmaceuticals (SUPN)
Neurocrine Biosciences (NBIX)
Incyte Corporation (INCY)
Immunovant (IMVT)
Agios Pharmaceuticals (AGIO)
Argenx Se Sponsored Adr (ARGX)
Novo-nordisk A S Adr (NVO)
Sanofi Sponsored Adr (SNY)
Alkermes SHS (ALKS)
Medtronic SHS (MDT)
Aurinia Pharmaceuticals (AUPH)

View all positions for Armistice Capital

Top funds holding Prothena

EcoR1 Capital
T. Rowe Price Associates
BlackRock
State Street Corporation
Palo Alto Investors
Armistice Capital
Vanguard Group
Henderson Group
Artal Group
Geode Capital Management
Dimensional Fund Advisors
Morgan Stanley
Boxer Capital
Rock Springs Capital Management
Citadel Advisors

View all funds holding Prothena